AR055295A1 - Compuestos inhibidores del transportador de glicina - Google Patents
Compuestos inhibidores del transportador de glicinaInfo
- Publication number
- AR055295A1 AR055295A1 ARP050105434A ARP050105434A AR055295A1 AR 055295 A1 AR055295 A1 AR 055295A1 AR P050105434 A ARP050105434 A AR P050105434A AR P050105434 A ARP050105434 A AR P050105434A AR 055295 A1 AR055295 A1 AR 055295A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- cycloalkyl
- group
- halophenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/50—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a compuestos de formula (1), o sus sales o solvatos de los mismos, para uso en la fabricacion de medicamentos para tratar trastornos neurologicos y neuropsiquiátricos, en particular psicosis, demencia o trastorno de déficit de atencion. La presente comprende adicionalmente procedimientos para preparar estos compuestos y las formulaciones farmacéuticas de los mismos. Reivindicacion 1: Un compuesto de la formula (1) o una sal o solvato del mismo en la que Z1 se selecciona entre el grupo constituido por alquilo C1-4, cicloalquilo C3-6, alquil C1-4tio, haloalquilo C1-4, fenilo, halofenilo, alquil C1-4sulfoxi, alquil C1-4sulfonilo, Cl, Br o I; Z2 se selecciona entre el grupo constituido por H, halogeno, alquilo C1-4, fenilo, haloalquilo C1-4, haloalcoxi C1-4, halofenilo, alcoxi C1-4-alquilo C1-4 y cicloalquilo C3-6; Z3 se selecciona entre el grupo constituido por H, halogeno, alquilo C1-4, alcoxi C1-4, alquil C1-4tio, haloalquilo C1-4, haloalcoxi C1-4, y cicloalquilo C3-6; Z4 se selecciona entre el grupo constituido por H, halogeno, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4, alquil C1-4tio, fenilo, haloalcoxi C1-4, halofenilo, alcoxi C1-4-alquilo C1-4 y cicloalquilo C3-6; Z5 se selecciona entre el grupo constituido por H, Cl, Br, I, hidroxi, alquilo C1-4, alcoxi C1-4, alquil C1-4tio, fenilo, haloalcoxi C1-4, halofenilo, alcoxi C1-4-alquilo C1-4 y cicloalquilo C3-6.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0428231A GB0428231D0 (en) | 2004-12-23 | 2004-12-23 | Compounds |
GB0509204A GB0509204D0 (en) | 2005-05-05 | 2005-05-05 | Compounds |
GB0524322A GB0524322D0 (en) | 2005-11-29 | 2005-11-29 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR055295A1 true AR055295A1 (es) | 2007-08-15 |
Family
ID=36030675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050105434A AR055295A1 (es) | 2004-12-23 | 2005-12-21 | Compuestos inhibidores del transportador de glicina |
Country Status (10)
Country | Link |
---|---|
US (1) | US20090270510A1 (es) |
EP (1) | EP1838663B1 (es) |
JP (1) | JP2008525399A (es) |
AR (1) | AR055295A1 (es) |
AT (1) | ATE421499T1 (es) |
DE (1) | DE602005012550D1 (es) |
ES (1) | ES2321217T3 (es) |
PE (1) | PE20061330A1 (es) |
TW (1) | TW200633956A (es) |
WO (1) | WO2006067417A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0428233D0 (en) * | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Compounds |
PE20061156A1 (es) | 2004-12-23 | 2006-12-16 | Glaxo Group Ltd | Derivados de benzamida como agentes inhibidores del transportador de glicina |
JP2008525398A (ja) * | 2004-12-23 | 2008-07-17 | グラクソ グループ リミテッド | グリシン輸送阻害剤 |
GB0600427D0 (en) * | 2006-01-10 | 2006-02-15 | Glaxo Group Ltd | Compounds |
GB0612437D0 (en) * | 2006-06-22 | 2006-08-02 | Glaxo Group Ltd | Compounds |
GB0612416D0 (en) * | 2006-06-22 | 2006-08-02 | Glaxo Group Ltd | Compounds |
US8080541B2 (en) * | 2009-08-27 | 2011-12-20 | Hoffman-La Roche Inc. | Carbocyclic GlyT-1 receptor antagonists |
SG186885A1 (en) | 2010-06-04 | 2013-02-28 | Albany Molecular Res Inc | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3145209A (en) * | 1961-07-31 | 1964-08-18 | Olin Mathieson | Substituted aminophenyl-ethylamine derivatives |
ATE412628T1 (de) * | 2001-07-17 | 2008-11-15 | Organon Nv | N- (1-dimethylaminocycloalkyl)methyl benzamid- derivate |
GB0130696D0 (en) * | 2001-12-21 | 2002-02-06 | Smithkline Beecham Plc | Chemical Compounds |
GB0428233D0 (en) * | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Compounds |
PE20061156A1 (es) * | 2004-12-23 | 2006-12-16 | Glaxo Group Ltd | Derivados de benzamida como agentes inhibidores del transportador de glicina |
JP2008525398A (ja) * | 2004-12-23 | 2008-07-17 | グラクソ グループ リミテッド | グリシン輸送阻害剤 |
GB0428232D0 (en) * | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Compounds |
-
2005
- 2005-12-16 PE PE2005001500A patent/PE20061330A1/es not_active Application Discontinuation
- 2005-12-21 EP EP05820721A patent/EP1838663B1/en active Active
- 2005-12-21 AR ARP050105434A patent/AR055295A1/es not_active Application Discontinuation
- 2005-12-21 DE DE602005012550T patent/DE602005012550D1/de active Active
- 2005-12-21 JP JP2007547626A patent/JP2008525399A/ja active Pending
- 2005-12-21 WO PCT/GB2005/004943 patent/WO2006067417A1/en active Application Filing
- 2005-12-21 TW TW094145552A patent/TW200633956A/zh unknown
- 2005-12-21 US US11/722,213 patent/US20090270510A1/en not_active Abandoned
- 2005-12-21 AT AT05820721T patent/ATE421499T1/de not_active IP Right Cessation
- 2005-12-21 ES ES05820721T patent/ES2321217T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
TW200633956A (en) | 2006-10-01 |
ATE421499T1 (de) | 2009-02-15 |
US20090270510A1 (en) | 2009-10-29 |
JP2008525399A (ja) | 2008-07-17 |
EP1838663B1 (en) | 2009-01-21 |
WO2006067417A1 (en) | 2006-06-29 |
PE20061330A1 (es) | 2006-12-27 |
DE602005012550D1 (de) | 2009-03-12 |
ES2321217T3 (es) | 2009-06-03 |
EP1838663A1 (en) | 2007-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR055295A1 (es) | Compuestos inhibidores del transportador de glicina | |
AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
ES2528451T3 (es) | Inhibidores de esfingosina cinasa | |
AR036103A1 (es) | Imidazotriazinas, procedimiento para su preparacion, uso de dichos compuestos para la manufactura de un medicamento para enfermedades neurodegenerativas y dicho medicamento | |
AR055296A1 (es) | Compuestos inhibidores del transportador de glicina | |
AR068051A1 (es) | Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer. | |
ECSP066383A (es) | Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias | |
AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
PE20200009A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
CO5700776A2 (es) | Compuestos utiles para el tratamiento de enfermedades | |
AR056892A1 (es) | Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa | |
AR064256A1 (es) | Sales y formas de cristal del 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-dihidro-imidazo-[4,5-c] -quinolin-1-il)-fenil] -propionitrilo | |
UY29919A1 (es) | Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones | |
AR036586A1 (es) | Nuevas dihidro-pteridinonas, procedimientos para su preparacion, su utilizacion como medicamentos y las formulaciones farmaceuticas que las contienen | |
AR064010A1 (es) | Inhibidores de la actividad de la akt | |
AR051997A1 (es) | Heterociclos triciclicos, su obtencion y uso delos mismos c omo agentes farmaceuticos | |
AR070520A1 (es) | Derivados de azuleno nitrogenados,composiciones farmaceuticas que los contienen,proceso de preparacion y usos de los mismos para tratar trastornos metabolicos y digestivos,entre otros. | |
AR050698A1 (es) | Compuesto de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para la preparacion de dicho compuesto | |
AR049711A1 (es) | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso | |
AR049577A1 (es) | Derivados de hidantoina, procesos para su preparacion, composiciones y su uso | |
CU20190046A7 (es) | Composición de concentrado orgánico que comprende ácido 2-{[5-{ 3-cloro-2-metil-4-[2-( 4-metilpiperazin-1-il)etoxi]fenil} -6-(4-fluorofenil)tieno[2,3-d]pirimidin-4-il]oxi}-3-(2-{ [2-(2-metoxifenil)pirimidin-4-il]metoxi} fenil)propanoico y, composiciones liposomales que la contienen | |
AR072263A1 (es) | Compuestos pirido-pirimidina que inhiben mtor composiciones farmaceuticas que los comprenden procesos para su preparacion y su uso como un medicamento | |
AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |